PR

ProGen, Co,, LTD.

Develops protein-based therapies for oncology, immune, and metabolic diseases.

296160 | KO

Overview

Corporate Details

ISIN(s):
KR7296160005
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172, 6층, 7층, 서울특별시

Description

ProGen is an R&D-focused biopharmaceutical company dedicated to developing innovative drugs for incurable diseases, with a primary focus on oncology, immune diseases, and metabolic disorders. The company specializes in creating novel protein-based immunotherapies and antibody therapeutics. Its research and development efforts are driven by proprietary technology platforms, including the NTIG (Neo Tri-ImmunoGlobulin) platform for next-generation multi-specific fusion proteins and the hyFc® platform for long-acting fusion proteins. These technologies enable the engineering of advanced bi-specific and multi-specific therapies designed to address significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-09-05 00:00
주식등의대량보유상황보고서(약식)
Korean 65.8 KB
2025-08-18 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 24.2 KB
2025-08-18 00:00
지정자문인선임계약의변경
Korean 5.1 KB
2025-07-15 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-07-11 00:00
주식등의대량보유상황보고서(약식)
Korean 99.0 KB
2025-07-07 00:00
주식등의대량보유상황보고서(약식)
Korean 122.5 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-11 00:00
주식매수선택권부여에관한신고
Korean 16.7 KB
2025-06-11 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 42.2 KB
2025-06-11 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 25.8 KB
2025-05-28 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean 43.5 KB
2025-05-23 00:00
주식등의대량보유상황보고서(약식)
Korean 123.5 KB
2025-05-23 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB

Automate Your Workflow. Get a real-time feed of all ProGen, Co,, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProGen, Co,, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProGen, Co,, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.